Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing new Tapestri Platform updates including lowered input threshold and expanded heme-onc menu. Learn More
X
Scientific presentation

Precision over bulk sequencing


Koichi Takahashi, MD
Dennis Eastbur, PhD
Jerry Radich, MD

Description

Fifty percent (50%) of patients with acute myeloid leukemia (AML) relapse and develop a more virulent form of the disease. To better understand AML and the cancer hematological ecosystem, it is necessary to discern clonal architecture and the dynamics of competing clones, which provide valuable insight into therapy response. It takes three or more mutations for leukemia to form. This can occur in the same cell or within the tumor microenvironment, but how do you discern this information with bulk sequencing? Dr. Jerry Radich, of Stanford Medical Center, and Dr. Koichi Takahashi, of MD Anderson, share their research on how they identified mutations within rare subclones using single-cell analysis for precision over bulk sequencing.



VIEW


Scientific presentation
Do More Single Cell with Less – Tapestri Platform Expansion for Hematologic Malignancy Research
Koichi Takahashi, MD, PhD, MD Anderson Cancer Center & Jim Flynn, PhD, Mission Bio
(2021)
Scientific presentation
Women in Single Cell: Elucidating Clonal Evolution and Clonotype-Immunophenotype Relationships in Myeloid Malignancies with Single-Cell Analysis
Linde Miles, PhD, Memorial Sloan Kettering Cancer Center
(2021)
Scientific presentation
Meet the Authors: Single-cell Multiomics Analysis of Clonal Evolution in Myeloid Malignancies
Ross Levine, MD, Memorial Sloan Kettering Cancer Center
(2021)
Scientific presentation
Utilizing Single-Cell Multi-Omics to Uncover its Evolution and Resistance Mechanisms of AML
Cathy Smith, MD, UCSF
(2021)
REQUEST QUOTE